Primary information |
---|
sequence ID | Seq_8103 |
Peptide sequence | TDQVLSVLKGEE |
CancerPDF_ID | CancerPDF_ID394, CancerPDF_ID9285, CancerPDF_ID9574, |
PMID | 19795908,24694173,21533267 |
Protein Name | Apolipoprotein C-II,Apolipoprotein C-II,Apolipoprotein C-II |
UniprotKB Entry Name | APOC2_HUMAN,APOC2_HUMAN,APOC2_HUMAN |
Fluid | Plasma,Ascites fluid,Serum |
M/Z | 659.35,NA,659.35 |
Charge | 2,1,2 |
Mass (in Da) | NA,NA,NA |
fdr | NA,NA,NA |
Profiling Technique | LC-MS,LTQ-Orbitrap XL,LC-MS |
Peptide Identification technique | MALDI-TOF/TOF,X tandem for peptide identification,LC/MS/MS |
Quantification Technique | LC-MRM (multiple reaction monitoring),NA,Multiple Reaction Monitoring |
Labelled/Label Free | Labelled,Label Free,Label Free |
FDR | less than 7%,NA,1.49 |
CancerPDF_ID | CancerPDF_ID394, CancerPDF_ID9285, CancerPDF_ID9574, |
p-Value | NA,NA,NA |
Software | FlexAnalysis 3.0 and Biotools 3.0 software,"X tandem for peptide identification,Scaffold 2 software for any modification analysis",MASCOT |
Length | 12,12,12 |
Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Ovarian cancer,Lung adenocarcinoma |
Database | NCBI refseq Protein Database,IPI00021856,Swissprot Database (57.4) |
Modification | NA,NA,NA |
Number of Patients | "41 normal, 24 patients",3 ovarian cancer patient and 3 non cancerous control,62 lung adenocarcinoma and 30 healthy control |
Regulation | NA,Uniquely expressed in ovarian cancer patient,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
Validation | NA,NA,MRM-based validation of 19 candidates |
Sensitivity | NA,NA,NA |
Specificity | NA,NA,NA |
Accuracy | NA,NA,NA |
Peptide Atlas | PeptideAtlas |
IEDB | |